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Abstract
Aims To compare reported level of bodily pain, overall and health-related quality of life (QoL), depression and fatigue
in people with long-term type 1 diabetes vs. a comparison group without diabetes. Further, to examine the associations
of total bodily pain with QoL, depression, fatigue and glycaemic control in the diabetes group.
Methods Cross-sectional study of 104 (76% of eligible) people with type 1 diabetes of ≥ 45 years’ duration attending
the Norwegian Diabetes Centre and 75 persons without diabetes who completed questionnaires measuring bodily pain
(RAND-36 bodily pain domain), shoulder pain (Shoulder Pain and Disability Index), hand pain (Australian/Canadian
Osteoarthritis Hand Index), overall QoL (World Health Organization Quality of Life – BREF), health-related QoL
(RAND-36), diabetes-specific QoL (Audit of Diabetes-Dependent Quality of Life; only diabetes group), depression
(Patient Health Questionnaire) and fatigue (Fatigue questionnaire). For people with type 1 diabetes, possible associations
between the bodily pain domain (lower scores indicate higher levels of bodily pain) and other questionnaire scores, were
measured with regression coefficients (B) per 10-unit increase in bodily pain score from linear regression.
Results The diabetes group reported higher levels of bodily (P = 0.003), shoulder and hand pain (P < 0.001) than the
comparison group. In the diabetes group, bodily pain was associated with lower overall and diabetes-specific QoL [B
(95% confidence intervals)]: 0.2 (0.1, 0.2) and 0.2 (0.1, 0.3); higher levels of depression 1.0 (1.3, 0.7) and total
fatigue 1.5 (1.9, 1.2); and worse glycaemic control HbA1c (mmol/mol; %) 0.8 (1.5, 0.1); 0.1 (0.1, 0.01).
Conclusions People with long-term type 1 diabetes experience a high level of bodily pain compared with a comparison
group. Total bodily pain was associated with worse QoL and glycaemic control.
Diabet. Med. 37, 1569–1577 (2020)
Introduction
A large proportion of people with long-term type 1 diabetes
suffer from vascular complications [1], of which both neu-
ropathy and cardiovascular disease may cause pain. Recent
studies have found that painful conditions in the upper
extremities affecting daily life are common in people with
long-term type 1 diabetes [2–5]. Moreover, like in the general
population, these people suffer from other painful conditions,
for example musculoskeletal, rheumatic or neurological
comorbidities. In addition, medications such as statins may
cause pain [6]. However, the level of bodily pain and its
influence on daily working capacity in people with long-term
type 1 diabetes have not yet been described.
Previous studies on pain and its associationswith depression
in long-term type 1 diabetes have been limited to neuropathy
and neuropathic pain [7] or to pain in the upper extremities
[2,3,5]. However, the pertinent pain burden for any individual
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is the total level of pain, regardless of bodily distribution or
cause. Moreover, total bodily pain and its association with
quality of life (QoL), depression, fatigue and glycaemic control
have not yet been studied in people with type 1 diabetes of
more than 25 years’ duration [8]. Therefore, we wanted to
describe and compare pain, QoL, levels of depressive symp-
toms and fatigue among people surviving more than 45 years
with type 1diabetes comparedwith a groupof personswithout
diabetes but of similar age, sex and socio-economic status.
Thus, we aimed to: (i) compare reported levels of bodily pain,
overall and health-related QoL, depression and fatigue in
people with long-term type 1 diabetes vs. a comparison group
without diabetes; and (ii) examine the association of reported
levels of bodily pain with QoL, depression, fatigue and
glycaemic control in the diabetes group.
Participants and methods
This work is part of the Dialong study, a cross-sectional
study in which all persons with type 1 diabetes diagnosed
before 1970 (n = 136) attending the Norwegian Diabetes
Centre (NDC) in Oslo, Norway, in 2015 were invited to
participate by mail.
The study group with type 1 diabetes was asked to invite
their spouse and/or close friends to participate in the
comparison group; exclusion criteria were first-degree rela-
tives, known diabetes or HbA1c > 48 mmol/mol (6.5%). The
comparison group participated at the same time and in the
same examinations as the diabetes group, except for the
diabetes-specific examinations (capillary blood glucose,
interview questions about hypoglycaemia, retina photos,
and diabetes-specific QoL).
In total, 104 people (77%) with long-term type 1 diabetes
and 75 members in the comparison group participated in the
study (Table 1). At the NDC, the diabetes participants’ charts
were reviewed by two physicians who registered data on
complications, comorbidities and medications. Participants
first visited the NDC to answer questionnaires and undergo
interviews and clinical examinations.Within threeweeks, they
attended Oslo University Hospital for fasting blood tests
(eGFR,HbA1c), urine sample (albuminuria), retina photos and
joint questionnaires. Details of the data collection methods
havebeenpublished elsewhere [9].Thequestionnaires assessed
participants’ reports of pain, QoL, depression and fatigue.
The Regional Committee for Medical and Health Research
Ethics South-East, Norway, approved the study (project no.
2014/851). Written informed consent was obtained from
each participant.
Patient-reported measures
We used Norwegian translated versions of all instruments
(Table 2 and Table S1), and these were scored according to
published algorithms [10–17].
Pain
The main study variable is the participant’s own rating of his/
her total bodily pain assessed by the bodily pain domain of
the widely used RAND-36, which includes two items: ‘How
much bodily pain have you had during the past 4 weeks?’,
and ‘During the past 4 weeks, how much did pain interfere
with your normal work (including both work outside the
home and housework)?’. We also analysed the two pain
items as separate variables. Higher scores indicate lower
levels of bodily pain and its interference with work [16].
Upper extremity pain severity and degree of difficulty with
activities of daily living requiring upper extremity use were
measured by the Shoulder Pain and Disability Index (SPADI)
[14]. Hand pain and functioning was measured by the
Australian/Canadian Osteoarthritis Hand Index (AUSCAN)
[15]. For both measures, higher scores indicate more and
worse symptoms. Participants were also asked: ‘Do you have
burning or aching pain in your feet or legs?’ (yes/no).
Quality of Life
Overall QoL was assessed by the first overall item of the
World Health Organization Quality of Life – BREF
(WHOQoL-BREF): during the previous two weeks: ‘How
would you rate your quality of life?’ [17]. Health-related
QoL was assessed by the RAND-36 physical and mental
component scores (PCS and MCS) [16]. Diabetes-specific
QoL was measured by the Audit of Diabetes-Dependent
Quality of Life (ADDQoL-18), which assesses how diabetes
affects QoL [10]. For all instruments, higher scores represent
better QoL.
Depression
The symptoms of depression were measured by the Patient
Health Questionnaire (PHQ-9) [13]; higher scores represent
higher symptom levels.
Fatigue
Extent and severity of fatigue was measured by the Fatigue
Questionnaire (FQ); higher scores represent higher levels of
fatigue. Chronic fatigue was identified as a duration of ≥ 6
months [11,12].
What’s new?
• Long-term survivors of type 1 diabetes are burdened by
several complications, conditions and medications that
may cause pain. However, a description of the level of
bodily pain is lacking.
• This study is the first to describe high levels of bodily
pain, which are associated with quality of life, in long-
term survivors of type 1 diabetes.
• A broader focus on pain is warranted and screening
tools should facilitate this.
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Comorbidities and medications
Glucose was measured using a capillary blood glucose meter
right after completing the questionnaires at the first visit at
the NDC. HbA1c, haemoglobin and thyroid-stimulating
hormone were measured by standard methods when attend-
ing Oslo University Hospital for fasting blood tests (second
visit) [9]. Hypoglycaemia (capillary blood glucose < 4 mmol/
l) and severe hypoglycaemia were defined as number of self-
reported episodes per month, and severe hypoglycaemia as a
hypoglycaemic episode requiring assistance from another
person for treatment.
Retinopathy, neuropathy, persistent albuminuria and past
cardiovascular event have been defined previously [9]. In
short, retinopathy was categorized as none, background or
proliferative. Neuropathy was defined based on the presence
of both typical symptoms in the lower extremities and
symmetrical signs in both lower extremities using standard
monofilament and vibration tests. Persistent albuminuria was
defined as a urinary albumin to creatinine ratio of > 2.9 mg/
mmol on two consecutive samples for the diabetes group and
one for the comparison group. Past cardiovascular event
included a diagnosis of coronary heart disease, cerebrovas-
cular disease or peripheral vascular disease. Hypothyroidism
was based on a recorded diagnosis of hypothyroidism or the
use of levothyroxine. Erectile dysfunction in men was defined
based on a self-reported ‘yes/no/unsure’ on whether they had
been unable to perform sexual intercourse or maintain
erection without aids/medications for the previous months/
years. Other painful chronic conditions included conditions
associated with pain, like intermittent claudication, angina
pectoris, rheumatic diseases, neurological comorbidity,
inflammatory bowel disease and lumbar disc herniation.
Self-reported daily use of painkillers (yes/no) included non-
steroidal anti-inflammatory drugs (NSAIDs) or other forms
of painkillers. We chose to define amitriptyline as a painkiller
because it is prescribed for neuropathic pain in diabetes and
is rarely used for depression in Norway. Anxiolytics was
defined as any use of benzodiazepines. Hypnotics were
generated from any use of zopiclone, zolpidem or alimema-
zine, and antidepressants from any use of paroxetine,
sertraline, venlafaxine, citalopram, escitalopram or mian-
serin.
Statistical analysis
Data are displayed as mean  SD, median (quartiles) or n
(%). We used t-tests with correction for unequal variances
between groups (or Wilcoxon rank-sum test if skewed data)
and chi-square tests to compare the clinical characteristics
and questionnaire scores between the study and comparison
groups.
In the type 1 diabetes group, we examined associations
between the primary variable of interest, the bodily pain
domain score of RAND-36, and the outcomes of overall QoL
(WHOQOL-BREF), diabetes-specific QoL (ADDQoL-18),
depression (PHQ-9), fatigue (FQ) and glycaemic control
(HbA1c), using bivariate and adjusted linear regression
analyses. The pain domain score of RAND-36 was divided
by 10 before inclusion in the regression models to obtain
regression coefficients per 10-unit change in bodily pain.
Higher scores on the pain domain score reflect less pain. To
examine if pain alone yielded different results, we repeated
the analysis with only item 7 of the RAND-36 bodily pain
domain (‘How much bodily pain have you had during the
past 4 weeks?’). We applied three different levels of adjust-
ment of known, possible confounders. First, we adjusted for
age, sex and education. We then added use of painkillers
daily as an additional adjustment variable and lastly, we
added glycaemic control (HbA1c). Successive addition of
adjustment variables did not change the regression coefficient
for bodily pain substantially and we therefore only reported
the final adjusted model. To make it possible to compare the
strength of the associations between different outcomes and
different measures of pain we also reported standardized
regression coefficients.
A P-value < 0.05 was considered statistically significant,
no adjustments were made for multiplicity of statistical tests.
All analyses were performed using STATA/SE 15.0.
Results
Of 136 eligible persons with long-term type 1 diabetes, 105
(77%) agreed to participate, of whom 104 (99%) completed
the questionnaires. All 75 persons (number of persons invited
unknown) agreeing to participate in the comparison group
completed the questionnaires. There were no statistically
significant differences between the two groups in age, sex,
education level, smoking status, or daily use of painkillers,
anxiolytics, hypnotics or antidepressants (Table 1). A statis-
tically significant higher percentage of the diabetes group
were living alone, not working and physically inactive.
Furthermore, relative to the comparison group they reported
more comorbidities, and more use of levothyroxine, statins,
aspirin and anti-hypertensive medication. They also had
lower haemoglobin and higher thyroid-stimulating hormone
levels.
Table 2 outlines the results from the questionnaires. Mean
bodily pain as measured by RAND-36 indicated higher levels
of bodily pain in the long-term type 1 diabetes group than in
the comparison group (66  28.2 vs. 78  24.1; P = 0.003),
lower scores indicate higher levels of bodily pain. Based on
RAND-36 item 7, ‘How much bodily pain have you had
during the past 4 weeks?’, the diabetes group was more likely
to experience moderate to very severe pain (44% vs. 29%;
P = 0.043) (Fig. 1). Among those experiencing moderate to
very severe pain, 17% in the diabetes group and 27% in
comparison group used painkillers daily. Relative to the
comparison group, the diabetes group reported more shoul-
der pain (SPADI Pain subscale score) (median 8.0 vs. 0.0;
ª 2020 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 1571
Research article DIABETICMedicine
P < 0.001), hand pain (AUSCAN Pain subscale) (mean  SD
score: 4.1  4.8 vs. 1.7  2.8; P < 0.001), and more pain in
their feet or legs (interview question) (26% vs. 5.3%;
P < 0.001). Other painful chronic conditions were similar
in the diabetes and comparison groups (50% vs. 44%)
(Table 1). Based on RAND-36 item 8, ‘During the past 4
weeks, how much did pain interfere with your normal work
(including both work outside the home and housework)?’,
the diabetes group reported more interference than the
comparison group (32% vs. 16%; P = 0.017) (Fig. 2).
The diabetes group reported lower overall QoL (WHO-
QoL-BREF) than the comparison group (mean  SD SCORE:
Table 1 Characteristics of the Norwegian Dialong study population of long-term type 1 diabetes and a comparison group without diabetes
Diabetes group n Comparison group n P-value
Sociodemographic
Age (years) 61  7.3 104 61  6.9 75 0.485
Sex male 52 (50) 104 34 (45) 75 0.538
Education college 64 (62) 104 55 (73) 75 0.099
Living alone 26 (25) 104 8 (11) 75 0.016
Working 44 (42) 104 45 (60) 75 0.019
Lifestyle factors
Physical inactivity* 10 (9.9) 101 1 (1.4) 74 0.021
Currently smoking 5 (4.8) 104 7 (9.3) 75 0.232
Diabetes-related factors
Glucose tested at visit 1, mmol/l 9.3  3.6 103 — —
HbA1c, mmol/mol 58  8.6 102 36  3.1 71 < 0.001
HbA1c, % 7.4  0.8 5.5  0.3
Diabetes duration, years 49 (45-54) 104 — —
Hypoglycaemia, number last month 12 (5.5-20) 104 — —
Severe hypoglycaemia last year (requiring assistance), yes 16 (15) 104
Number of times, median (min-max) 2 (1-10) 16
Morbidity
Retinopathy†
None 5 (4.8) 104 — —
Background 54 (52) 104 — —
Proliferative 45 (43) 104 — —
Neuropathy‡ 66 (64) 104 16 (21) 75 < 0.001
Persistent albuminuria§ 17 (16) 104 4 (5.5)¶ 73 0.028
eGFR < 60 9 (8.7) 104 2 (2.7) 75 0.100
Hypothyroidism‖ 36 (35) 104 9 (12) 75 0.001
Erectile dysfunction in men 24 (46) 52 6 (18) 34 0.019
Past cardiovascular event** 21 (20) 104 6 (8.0) 75 0.025
Other painful chronic conditions†† 52 (50) 104 33 (44) 75 0.428
Medication
Painkillers, daily 10 (9.6) 104 6 (8.0) 75 0.924
Anxiolytics 2 (1.9) 104 2 (2.7) 75 0.740
Hypnotics 6 (5.8) 104 1 (1.3) 75 0.131
Antidepressants 6 (5.8) 104 1 (1.3) 75 0.131
Sleep medication/anxiolytics and hypnotics 7 (6.7) 104 3 (4.0) 75 0.433
Anxiolytics or antidepressants 8 (7.7) 104 3 (4.0) 75 0.310
Levothyroxine 23 (22) 104 3 (4.0) 75 0.001
Statins 56 (54) 104 12 (16) 75 < 0.001
Acetylsalicylic acid (ASA) 33 (32) 104 9 (12) 75 0.002
Antihypertensives 56 (54) 104 18 (24) 75 < 0.001
Laboratory variables
Haemoglobin g/dl 14.0  1.3 102 14.5  1.0 73 0.013
Thyroid-stimulating hormone (TSH) mU/l 2.6  2.0 99 1.9  1.0 71 0.014
Data are mean  SD, median (quartiles) or n (%) unless otherwise stated.
*Physical inactivity was defined as < 30 min of fast walking 1–2 times a week.
†Retinopathy was categorized as either none, background or proliferative (pan-retinal photocoagulation scars or proliferative findings)
retinopathy based on retina photos.
‡Neuropathy was defined based on the presence of both typical symptoms in the lower extremities (numbness, unsteadiness, aching or
burning pain or pins and needles) and symmetrical signs in both lower extremities using standard monofilament and vibration tests.
§Persistent albuminuria was defined as an albumin/creatinine ratio of > 2.9 mg/mmol on two consecutive samples.
¶Based on one urine sample measuring albumin/creatinine ratio.
Based on hypothyroidism diagnosis or use of thyroxin.
**Past cardiovascular event included a diagnosis of coronary heart disease (previous verified angina, acute coronary syndrome or
revascularization), cerebrovascular disease or peripheral vascular disease.
††Other painful chronic conditions including conditions associated with pain, like intermittent claudication, angina pectoris, rheumatic
diseases, neurological comorbidity excluding peripheral diabetic neuropathy, inflammatory bowel disease and lumbar disc herniation.
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3.4  1.1 vs. 4.0  0.8; P < 0.001), lower health-related
QoL measured by the RAND-36 PCS (mean  SD: 49.9 
11.6 vs. 57.6  8.1; P < 0.001) but not in the MCS (mean 
SD score: 38.6  7.0 vs. 39.4  4.9; P = 0.399). The diabetes
group reported higher levels of depressive symptoms (PHQ-
9) (mean  SD score: 6.3  4.9 vs. 4.0  3.6; P < 0.001),
and a higher prevalence (19% vs. 8.0%; P = 0.035) of
clinically significant depression. They also reported more
chronic fatigue (35% vs. 6.7%; P < 0.001) as measured by
the FQ (score > 4) (Table 2).
In regression analysis of the type 1 diabetes group, bodily
pain (RAND-36) was associated with QoL, depression,
fatigue and glycaemic control (HbA1c), with lower scores
on bodily pain, indicating higher influence of bodily pain
(Table 3). Bodily pain was associated with overall QoL
(WHOQOL-BREF) [adjusted regression coefficients (B)
(95% confidence intervals) and standardized regression
coefficients: 0.2 (0.1, 0.2) and 0.4] and diabetes-specific
QoL (ADDQoL-18) [0.2 (0.1, 0.3) and 0.5], indicating that
more pain was associated with lower general and diabetes-
specific QoL. Further, more bodily pain was associated with
higher levels of depressive symptoms (PHQ-9) [1.0 (1.3,
0.7) and 0.6], fatigue (FQ) [total 1.5 (1.9, 1.2) and
0.7; physical 1.1 (1.4, 0.9) and 0.7; mental 0.4
(0.6, 0.3) and0.6], and worse glycaemic control (HbA1c
mmol/mol; %) [0.8 (1.5, 0.1); 0.1 (0.1, 0.01) and
Table 2 Questionnaire scores in the long-term type 1 diabetes group vs. the comparison group
Diabetes group n* Comparison group n* P-value
Pain
RAND-36
Bodily pain domain score [0–100]† 66  28.2 104 78  24.1 75 0.003
Item 7: ‘How much bodily pain have you
had during the past 4 weeks?’
Moderate/severe/very severe pain
46 (44) 104 22 (29) 75 0.043
Item 8: ‘During the past 4 weeks, how much did
pain interfere with your normal work (including
both work outside the home and housework)?’
Moderate/quite a bit/extreme interference
33 (32) 104 12 (16) 75 0.017
Upper and lower extremities
SPADI Index score [0–100]†,‡ 8.1 (1.6–37.0) 102 0.6 (0.0–7.1) 72 < 0.001
SPADI Pain subscale [0–100]†,‡ 8.0 (0.0–38.0) 102 0.0 (0.0–11.0) 72 < 0.001
AUSCAN Index score [0–60]† 13.4  13.0 101 5.0  7.4 73 < 0.001
AUSCAN Pain subscale [0–20]† 4.1  4.8 101 1.7  2.8 73 < 0.001
Interview question: ‘Do you have burning or
aching pain in your feet or legs?’ ‘Yes’
27 (26) 104 4 (5.3) 75 < 0.001
Quality of Life (QoL)
Overall QoL
WHOQoL-BREF [1–5]† 3.4  1.1 102 4.0  0.8 74 < 0.001
Health-related QoL
RAND-36 Component Scores
Physical Component Score (PCS) 49.9  11.6 99 57.6  8.1 73 < 0.001
Mental Component Score (MCS) 38.6  7.0 99 39.4  4.9 73 0.399
Diabetes-specific QoL
ADDQoL-18 [9 to +9]† 1.3 (2.3, 0.7) 100 NA NA NA
Depression
PHQ-9 [0–27] † 6.3  4.9 104 4.0  3.6 75 < 0.001
PHQ-9 Clinically significant depression (score ≥10) 20 (19) 104 6 (8.0) 75 0.035
Fatigue
FQ Total fatigue [0–33]† 15.2  6.1 104 11.6  3.0 75 < 0.001
FQ Physical fatigue [0–21]† 10.3  4.5 104 7.5  2.6 75 < 0.001
FQ Mental fatigue [0–12]† 4.9  2.1 104 4.1  1.0 75 0.003
FQ Chronic fatigue (total) (score >4) 36 (35) 104 5 (6.7) 75 < 0.001
FQ Chronic physical fatigue (score >4) 32 (31) 104 4 (5.3) 75 < 0.001
FQ Chronic mental fatigue (score >4) 0 104 0 75
Unless otherwise stated, numbers presented are mean  SD, median (quartiles) or n (%).
NA, not applicable.
*Total population (n) varies some for each characteristic reliant on the actual completion of the diverse questionnaires (missing range
diabetes group: 0–5; comparison group: 0–3).
†Scoring scales. For the Shoulder Pain and Disability Index score (SPADI), Australian/Canadian Osteoarthritis Hand (AUSCAN), Patient
Health Questionnaire (PHQ-9) and Fatigue Questionnaire (FQ) a higher score indicates more symptoms and is worse. For the RAND-36,
World Health Organization Quality of Life-BREF (WHOQOL-BREF) and Audit of Diabetes-Dependent Quality of Life (ADDQoL-18) a
higher score indicates better quality of life.
‡Wilcoxon rank-sum test (due to skewed data).
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0.3]. Adjustments for age, sex, education, use of painkillers
daily and HbA1c did not change results markedly.
When using RAND-36 Item 7, ‘How much bodily pain
have you had during the past 4 weeks?’, as the indicator of
pain there were only small differences in the standardized
regression coefficients (model 2 compared with model 1).
Adjustments for age, sex, education, painkillers daily and
HbA1c did not change results markedly.
Discussion
People with long-term type 1 diabetes experienced statisti-
cally significantly higher levels of bodily pain, worse QoL,
worse physical health, higher levels of depressive symptoms
and fatigue compared with a group similar in age, sex and
socio-economic status without diabetes. In the diabetes
group, bodily pain was associated with worse QoL, higher






FIGURE 1 Pain severity. RAND36 – item 7: How much bodily pain have you had during the past 4 weeks?. Moderate/severe/very severe pain in
long-term type 1 diabetes was 44% vs. 29% in the comparison group. P = 0.043.




Not at all A little bit
Moderately Quite a bit
Extremely
FIGURE 2 Pain interference. RAND36 – item 8: During the past 4 weeks, how much did pain interfere with your normal work (including both work
outside the home and housework)? Moderate/quite a bit/extreme interference in long-term type 1 diabetes was 32% vs. 16% in the comparison
group. P = 0.017.
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levels of depressive symptoms and fatigue, and worse
glycaemic control.
The percentage of people with long-term type 1 diabetes
reporting moderate to very severe bodily pain was more than
twice as high as the percentage using painkillers daily (44%vs.
17%).There is awell-knownassociation betweendiabetes and
pain [18], and recent studies have found increased levels of
pain amongpeoplewith long-term type 1diabetes [2–5]. There
are several possible underlying aetiologies. The prevalence of
painful conditions in the upper extremities is relatively high
(38–64%) in participants with a shorter diabetes duration
[2,4].We have previously reported a lifetime prevalence of one
or more hand or shoulder diagnoses (frozen shoulder,
Dupuytren’s disease, trigger finger, carpal tunnel syndrome)
as high as 94% [9] and a large percentage experienced pain
(and disability) in their upper extremities, as reflected by the
pain subscale scores in SPADI and AUSCAN, reflecting
increasing levels of pain with increasing diabetes duration.
Moreover, 26% reported burning or aching pain in their feet
or legs, indicating peripheral diabetic neuropathic pain. In a
Canadian study of longevity in type 1 diabetes, the prevalence
of neuropathic pain was 36%; only 8.9% of these used
neuropathic pain medications and 16% used other pain
medications [19]. Total bodily pain in the present study was
associated with worse QoL in people with long-term type 1
diabetes. Thus, there is a need for more attention on pain in
clinical consultations.
Higher levels of bodily pain were associated with higher
levels of depressive symptoms. This finding is in contrast to
the only other study on pain and depression in long-term type
1 diabetes we identified [7]. In the Canadian study of
longevity, neuropathy was associated with depression, inde-
pendent of neuropathic pain, and other vascular complica-
tions that might cause pain, like cardiovascular disease, were
not associated with depression [7]. By contrast, in a
longitudinal study in which most participants had type 2
diabetes, neuropathy was a risk factor for depressive symp-
toms because it generated pain and unsteadiness [20]. As we
Table 3 Unadjusted and adjusted linear regression analyses of the associations of RAND-36 bodily pain domain with QoL, depression, fatigue and










Model 1: RAND-36 Bodily pain domain
Overall QoL
(WHOQoL-BREF)
0.2 (0.1, 0.2) 0.5 102 0.2 (0.1, 0.2) 0.4 100
Diabetes-specific QoL
(ADDQoL-18)
0.2 (0.1, 0.3) 0.5 100 0.2 (0.1, 0.3) 0.5 99
Depression (PHQ-9) 1.1 (1.4, 0.8) 0.6 104 1.0 (1.3, 0.7) 0.6 102
Fatigue
FQ Total 1.5 (1.8, 1.2) 0.7 104 1.5 (1.9, 1.2) 0.7 102
FQ Physical 1.1 (1.4, 0.9) 0.7 104 1.1 (1.4, 0.9) 0.7 102
FQ Mental 0.4 (0.5, 0.3) 0.5 104 0.4 (0.6, 0.3) 0.6 102
Glycaemic control
HbA1c, mmol/mol 0.9 (1.5, 0.3) 0.3 102 0.8 (1.5, 0.1) 0.3 102
HbA1c, % 0.1 (0.1, 0.03) 0.3 102 0.1 (0.1, 0.01) 0.3 102
Model 2: RAND-36, Item 7 ‘How much bodily pain have you had during the past 4 weeks?’
‘How much bodily pain have you had during the past 4 weeks?’
Overall QoL
(WHOQoL-BREF)
0.3 (0.1, 0.4) 0.4 102 0.2 (0.1, 0.4) 0.3 100
Diabetes-specific QoL
(ADDQoL-18)
0.4 (0.2, 0.5) 0.4 100 0.3 (0.2, 0.5) 0.4 99
Depression (PHQ-9) 1.9 (2.4, 1.4) 0.6 104 1.6 (2.2, 1.0) 0.5 102
Fatigue
FQ Total 2.7 (3.3, 2.1) 0.7 104 2.5 (3.2, 1.8) 0.6 102
FQ Physical 2.0 (2.4, 1.6) 0.7 104 1.9 (2.4, 1.4) 0.7 102
FQ Mental 0.7 (0.9, 0.4) 0.5 104 0.6 (0.9, 0.3) 0.5 102
Glycaemic control
HbA1c, mmol/mol 1.6 (2.7, 0.5) 0.3 102 1.5 (2.7, 0.2) 0.3 102
HbA1c, % 0.1 (0.2, 0.04) 0.3 102 0.1 (0.3, 0.02) 0.3 102
Respondents with missing values on any of the explanatory variables were excluded from the regression analyses, giving a sample size ranging
from 99 to 104.
For RAND-36 bodily pain domain, the higher the score, the less influence of bodily pain on quality of life. For the World Health Organization
Quality of Life-BREF (WHOQOL-BREF) and Audit of Diabetes-Dependent Quality of Life (ADDQoL-18), a higher score is better. For the
Patient Health Questionnaire (PHQ-9) and Fatigue Questionnaire (FQ) a higher score indicates more depressive symptoms or fatigue.
*The unstandardized regression coefficients measure change in the outcome per 10-unit change in RAND-36 bodily pain domain and per 1-
unit change for RAND-36 item 7.
†Adjusted for age, sex, education, painkillers daily and HbA1c.
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studied the level of total bodily pain, we did not control for
complications that might mediate the effect of diabetes. The
association between bodily pain and depression in our study
might reflect supplementary or different mechanisms.
Prospective studies of long-term type 1 diabetes should
explore such mechanisms more closely.
We found a weak association between more bodily pain
and worse glycaemic control. Prior studies show conflicting
results regarding pain and glycaemic control. Menting et al.
[8] found no association in a group of severely fatigued
people with type 1 diabetes duration of 25 years. An
association of hand and shoulder pain with worse long-term
HbA1c was shown previously in our study population [3,5],
and in a Swedish study of current HbA1c and shoulder
impairment [2].
The study participants had several conditions associated
with bodily pain, including a past cardiovascular event
(20%) and other painful chronic conditions (50%), in
addition to the use of statins (54%). These conditions are
associated with different pain patterns and require different
medical management plans. This emphasizes the need for a
systematic focus on pain by including patient-reported
outcome measures and organ/disease-specific examination
to be able to diagnose and treat pain sufficiently in the
routine care for people with long-term type 1 diabetes.
Strengths of this study include having a population
surviving more than 45 years with type 1 diabetes who are
phenotypically well characterized by extensive examinations
and with a high response rate on the questionnaires.
Moreover, there were no differences in background data
between fully included participants and participants allowing
a chart review [21]. Our sample should give a reasonable
representation of those with diabetes who were invited to
participate. Further, the mean HbA1c among our long-term
type 1 diabetes group was similar to that for the Norwegian
type 1 diabetes population of more than 45 years duration
[9]. However, our study has limitations. The cross-sectional
design cannot assess causal relations. In addition, because
members of the comparison group had a close relationship to
a member of the study group, they were not independent
observations. However, the groups were well matched in age
and education. Further, the regression coefficients were
relatively small and may not be clinically significant, due to
type 2 error. Finally, due to the exploratory analysis with
multiple comparisons we cannot rule out that some of the
significant P-values are due to chance.
In conclusion, people with long-term type 1 diabetes
experience high levels of total bodily pain, worse quality of
life, and worse physical health, as well as higher levels of
depressive symptoms and fatigue compared with a compar-
ison group of similar age, sex and socio-economic status.
Bodily pain was associated with worse quality of life, higher
levels of depressive symptoms and fatigue, and worse
glycaemic control. Pain is a condition with multiple possible
underlying aetiologies, but one for which treatment is
available, and more effective treatment of these conditions
has potential to improve QoL in this group. Clinical
guidelines for diabetes refer only to painful neuropathy
[22], but a broader focus is warranted. To promote a
systematic focus on total bodily pain, participant-reported
outcome measures such as questionnaires could be useful as
screening tools that hopefully will lead to more pain
recognition and treatment, resulting in better QoL.
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